merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>Skepticism surrounding Kisunla's approval stems from concerns about its safety risks and modest benefits.</answer>

<question_number>2</question_number>
<answer>The focus on anti-amyloid drugs might discourage patients from participating in trials for potentially better treatments.</answer>

<question_number>3</question_number>
<answer>Dr. Greicius states that there is no correlation between amyloid plaque removal and clinical response in individual patients.</answer>

<question_number>4</question_number>
<answer>N/A</answer>

<question_number>5</question_number>
<answer>The higher price of Kisunla might be justified because patients can potentially stop treatment after amyloid is cleared, reducing overall cost and inconvenience.</answer>

<question_number>6</question_number>
<answer>The article suggests that the emphasis on anti-amyloid drugs might discourage patients from participating in other clinical trials.</answer>

<question_number>7</question_number>
<answer>Kisunla may reduce treatment inconvenience because it is given monthly, and patients can potentially stop treatment after amyloid is cleared.</answer>

<question_number>8</question_number>
<answer>Amyloid</answer>

<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>

<question_number>10</question_number>
<answer>Tau levels; patients with intermediate tau levels declined more slowly on donanemab than those with high levels.</answer>